TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Two deaths involving counterfeit versions of investigational weight-loss drug retatrutide were reported to the FDA, according to a MedPage Today roundup citing CBS News. Separately, Novo Nordisk plans to discontinue its liraglutide injection Saxenda in early 2027 because of declining sales; the roundup also reports an association between PMOS and dementia risk, but does not establish causation.
Two deaths involving counterfeit versions of retatrutide, an investigational weight-loss drug, were reported to the U.S. Food and Drug Administration, according to a MedPage Today endocrinology roundup published October 13, citing CBS News. The roundup also says Novo Nordisk plans to discontinue Saxenda, its liraglutide weight-loss injection, in early 2027 because of declining sales; it does not link the two developments.
The report describes the retatrutide cases as involving counterfeit versions of a medicine that is still investigational. It says the deaths were reported to the FDA, but gives no details about when or where they occurred, the products involved, or whether investigators established that the counterfeit drug caused the deaths. The reports concern suspected counterfeit products, not evidence in the material that authentic retatrutide caused fatalities.
Novo Nordisk’s planned Saxenda discontinuation is a separate commercial development. The roundup attributes the decision to declining sales and places the planned withdrawal in early 2027. It does not provide a precise end date, explain which markets will be affected, or say how patients currently using the injection will be supported.
The roundup also summarizes a report in the Journal of the Endocrine Society suggesting that dementia and Alzheimer’s disease may be more common in women with polyendocrine metabolic ovarian syndrome (PMOS), formerly called polycystic ovary syndrome (PCOS). It says the association is likely driven by metabolic conditions occurring alongside PMOS. That is an association, not proof that PMOS itself causes dementia.
Safety Reports and Saxenda Access
The counterfeit-drug reports underline the potential danger of obtaining an investigational medicine from unverified sources. Retatrutide is not described here as an approved weight-loss treatment, and the source material does not establish the cause of the deaths. Readers should distinguish reports involving counterfeit products from findings about a medicine’s safety when tested in clinical studies.
The planned Saxenda discontinuation could affect people who use liraglutide for weight management, but the available report leaves practical details unanswered. Declining sales are the stated reason; the roundup does not report a safety withdrawal or specify whether availability will end everywhere at the same time. The PMOS finding also merits careful reading: a reported link with dementia does not show that one condition causes the other.
retatrutide weight loss medication
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Three Separate Endocrinology Updates
These items appeared together in MedPage Today’s October 13 endocrinology roundup, which collected updates across obesity treatment, hormone-related conditions and other areas. The source cites CBS News for the counterfeit retatrutide deaths, NPR for ongoing lawsuits alleging severe adverse events from GLP-1 receptor agonists, and the Journal of the Endocrine Society for the PMOS and dementia association. The lawsuits are allegations, not findings described as proven in the supplied material.
The same roundup notes that the World Health Organization issued obesity guidelines for children and adolescents, recommending against weight-loss drugs or bariatric surgery for patients younger than 10. It also reports that prescriptions for oral semaglutide for weight management passed 100,000 within two months of its approval. These developments offer broader industry context but are not stated to be connected to the counterfeit retatrutide reports or Saxenda’s planned discontinuation.
“Two recent deaths tied to counterfeit versions of retatrutide, an investigational weight-loss medication, were reported to the FDA.”
— MedPage Today roundup, citing CBS News
As an affiliate, we earn on qualifying purchases.
Details Behind the Reports
The source summary does not identify the counterfeit products, say whether they contained retatrutide or another substance, or provide information about the people who died. It also does not report whether the FDA or another authority has completed an investigation. A report to the FDA is not, by itself, proof that a product caused a death.
For Saxenda, the precise discontinuation date, affected countries, supply timeline and plans for current users are not given. The PMOS summary likewise offers no study design, participant numbers or effect estimates, so readers cannot assess the size of the reported association from this material alone. The connection to metabolic comorbidities is presented as a likely explanation, not a confirmed mechanism.
As an affiliate, we earn on qualifying purchases.
FDA Review and Saxenda Timeline
Further information from the FDA or reporting on its review may clarify the counterfeit retatrutide cases, including what products were involved and whether a causal link was found. Until more is available, the reported deaths should be described as involving counterfeit versions and not treated as proof that authentic investigational retatrutide caused harm.
Novo Nordisk’s stated plan points to early 2027 for Saxenda’s discontinuation. Details about markets, supply and guidance for current users remain outstanding in the supplied report. Patients with questions about treatment availability should seek information from their prescribing clinician or relevant local health authorities rather than assume that another medication is a direct replacement.
As an affiliate, we earn on qualifying purchases.
Key Questions
What was reported about retatrutide?
A MedPage Today roundup citing CBS News said two deaths involving counterfeit versions of investigational retatrutide were reported to the FDA. The summary does not establish that the products caused the deaths.
Does this report say authentic retatrutide caused deaths?
No. It refers to counterfeit versions and does not provide an investigation finding or establish causation. Details about the products and cases are not included in the supplied report.
When is Saxenda expected to be discontinued?
Novo Nordisk plans to discontinue the liraglutide injection in early 2027, according to the roundup. It attributes the plan to declining sales but does not specify the exact date or markets affected.
Does PMOS cause dementia?
The roundup reports a possible association between PMOS and higher rates of dementia and Alzheimer’s disease among women. It says the link is likely driven by metabolic comorbidities; the summary does not establish that PMOS causes dementia.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
